European bioregions : strengths and partnership strategies. The - PowerPoint PPT Presentation

EU Initiative Promoting SME Internationalisation Through Clusters European bioregions : strengths and partnership strategies. The bioXclusters example BioPartnering Latin America – cluster forum – september 2013 This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry and financed under the Competitiveness and Innovation Framework Programme (CIP) and financed under the Competitiveness and Innovation Framework Programme (CIP)

EU Initiative Promoting SME Internationalisation Through Clusters Contents Who we are Our goals Our activities Wha we can offer What we will represent in the future This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry 2 23 April, 2013 and financed under the Competitiveness and Innovation Framework Programme (CIP)

EU Initiative Promoting SME Internationalisation Through Clusters Why to cooperate?  mutual learning  exchange of good practice  joint business opportunities  development of common strategies  exchange of qualified staff  mobility of firms  sharing incubation facilities  mutually sharing access to networks and international partnerships  access to international markets and business development in new market  mutually exchange technical competences  share research infrastructure and production facilities  economies of scale This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry May 2013 and financed under the Competitiveness and Innovation Framework Programme (CIP)

EU Initiative Promoting SME Internationalisation Through Clusters bioXclusters Regional clusters partnership This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry May 2013 4 and financed under the Competitiveness and Innovation Framework Programme (CIP)

EU Initiative Promoting SME Internationalisation Through Clusters Who are we? bioXclusters is a European initiative, funded by the European Commission, uniting 4 regions in Europe with one single approach: Supporting the competitiveness of European clusters’ SMEs by facilitating internationalisation and access to global markets This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry 5 May 2013 and financed under the Competitiveness and Innovation Framework Programme (CIP)

EU Initiative Promoting SME Internationalisation Through Clusters Our assets MAIN THERAPEUTIC TECHNOLOGY SECTORS AREAS SPECIALITIES Biotechnology Oncology Personalised Medicine Health care Cardiovascular Nanomedicine Biomedicine Infectious diseases Targeted therapies Regenerative Med. Inflamatory diseases Drug Development Biopharmaceutical Neurological diseases Medical technologies Diagnostics Autoimmune diseases Diagnostics Solutions This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry 6 May 2013 and financed under the Competitiveness and Innovation Framework Programme (CIP)

EU Initiative Promoting SME Internationalisation Through Clusters Four European partners This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry May 2013 7 and financed under the Competitiveness and Innovation Framework Programme (CIP)

EU Initiative Promoting SME Internationalisation Through Clusters 1997 – Barcelona Science The Bioregion of Park was created Catalonia • Main biotech hub in 2006 – Creation of Biocat Spain – Private Foundation • 480 companies • 435 Research Groups Promotes and develops • 10 Universities life sciences in Catalonia • 3 Large-scale R&D Visit us in www.biocat.cat 2013 – Launch of the First Infrastructures Catalonia (Spain) Edition of Design Health • 15 university hospitals Follow us on twitter Barcelona program with capital in (@biocat.en) and • 20 Science parks Linkedin Barcelona Main Therapeutic Areas INTERNATIONALIZATION/GLOBALIZATION: Fostering talent • Oncology Facilitating access to markets through: • Neurosciences • • Network of local contacts in foreign markets Cardiovascular • • Agreements with science parks and other Dermatology d·HEALTH Barcelona organizations Main Interests : Technological www.moebio.org Strengths • USA • Nanobiomedicine • Asia (China, Japan & India) • Organization of Genomics & • South America Structural Biology BIoEurope Spring Member of CEBR – Council of • Drug Design 2010 & 2013 European Bioregions & EDCA • Bioinformatics This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry May 2013 and financed under the Competitiveness and Innovation Framework Programme (CIP)

EU Initiative Promoting SME Internationalisation Through Clusters 1989 - Foundation of first 338 biotech & biotech SME pharma companies: 178 biotech SMEs Germany 37 biotech non-SMEs 1997- Establishment of 37 pharma companies Bio M cluster organisation 86 CROs & suppliers 2010 – Start of Munich 26.000 employees Initiative for Personalized in total, Medicine (www.m4.de) 4.300 in biotech SMEs Bio M Biotech Cluster Development GmbH Bavaria (Germany) www.bio-m.org and Greater Munich “m4 Initiative for Personalised Medicine & INTERNATIONALIZATION / GLOBALIZATION: Targeted Therapies, Personalized Therapeutics & Medicine & Targeted Growth through partnerships and Diagnostics, Devices, Therapies”: collaborations in Europe and worldwide. Analytics, Informatics 100 mio € for 5 years, Main interest of members: Oncology, 35 R&D projects, Cardiovascular diseases Asia (China & Japan) and USA 5 infrastructure projects, Autoimmune diseases m4 Award for start-ups, Member of CEBR – Council of European Close collaboration with collaborations between Bioregions regional medtech network SMEs and academia / hospitals. This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry May 2013 and financed under the Competitiveness and Innovation Framework Programme (CIP)

EU Initiative Promoting SME Internationalisation Through Clusters 1999- Science park 400-in total creation 270 health care 7.000 employees 2009-Cluster SME No: 95% initiative inception 27 MNC bioPmed health care 3900 scientist in cluster R&D institutions Bioindustry Park Piemonte region Silvano Fumero SpA (Italy) Science park Main city Torino www.biopmed.eu www.bioindustrypark.eu (Turin) • Personalised health ALISEI Member INTERNATIONALIZATION/GLOBALIZATION: care/Converging Growth through partnerships and collaborations technologies 14+ MOU with international actors Bioeurope Spring • Innovative biomedical 147 SMEs supported (last 4 years) 2014 in Torino 10+ international projects ongoing and realized devices (Prosthesis) CEBR – Council of European Bioregions • Imaging • Regenerative 30 R&D projects 2 Multinational corporations as shareholder of medicine the science park launched involving • Oncology, CNS, Metaclustering approach to have 70 actors in the last Autoimmune diseases critical mass based on 4 years • Start-up creation complementarities This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry May 2013 and financed under the Competitiveness and Innovation Framework Programme (CIP)

EU Initiative Promoting SME Internationalisation Through Clusters >2005 – Establishment + 500 companies in health care of the French cluster + 30 000 employees policy and creation of + 4 000 scientists Lyonbiopole >4 World Class leaders: bioMérieux, Sanofi, BD, >2012 – EU Bronze Merial. Label Awarded and >8 International R&D Rhone-Alpes Lyonbiopole assessed Infrastructures LYONBIOPOLE Region (France) as the most performing >130 official members Rhone-Alpes BioCluster French BioCluster Main cities www.lyonbiopole.com > 134 R&D projects = Lyon & Grenoble total of € 667 million Infectious diseases INTERNATIONALIZATION/GLOBALIZATION: Immune Disorders >Internationalization based on a dual 7 500 sq.m of biomanufacturing & Cancers bioanalysis labs approach: interclustering and support to SMEs. Personalized medicine >3 main target markets: North America (USA + 1 920sq.m of BSL Biotherapies & Vaccines Canada), Brazil & China 2/3 Labs Diagnostics >One representative based in Shanghai Delivery systems Devices >Member of CEBR – Council of European Technological Research Institute on Infectious Diseases & Microbiology Bioregions & EDCA Close collaboration with European Network on regional medtech network >In 2012: + 50 companies supported System Biology & & 6 international trade missions Medicine This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry May 2013 and financed under the Competitiveness and Innovation Framework Programme (CIP)

EU Initiative Promoting SME Internationalisation Through Clusters Our goals and activities This initiative is supported by the European Commission’s Directorate -General for Enterprise and Industry May 2013 12 and financed under the Competitiveness and Innovation Framework Programme (CIP)